The substantial downgrade in guidance from 45% - 55% to 10% - 15% 2017 top line growth is clearly very disappointing. We believe the decrease largely results from smaller than anticipated sample volumes and delays in a large Medicare-funded ConfirmMDx post-marketing study as well as contractual delays related to the flow of billable cases from one or more of its larger customers with whom it has service agreements. The company will provide a more detailed analysis and hopefully better guidance at the time of its FY results expected February 22nd. We remain positive as to the longer term prospects for the MDxH's prostate cancer tests Confirm- and SelectMDx. However, given the immediate uncertainty, we are placing our forecasts, target price and recommendation under review.
29 Dec 2017
Contractual delays drive downgrade
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Contractual delays drive downgrade
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
29 Dec 2017 -
Author:
Chris Redhead -
Pages:
5
The substantial downgrade in guidance from 45% - 55% to 10% - 15% 2017 top line growth is clearly very disappointing. We believe the decrease largely results from smaller than anticipated sample volumes and delays in a large Medicare-funded ConfirmMDx post-marketing study as well as contractual delays related to the flow of billable cases from one or more of its larger customers with whom it has service agreements. The company will provide a more detailed analysis and hopefully better guidance at the time of its FY results expected February 22nd. We remain positive as to the longer term prospects for the MDxH's prostate cancer tests Confirm- and SelectMDx. However, given the immediate uncertainty, we are placing our forecasts, target price and recommendation under review.